Rodman & Renshaw analyst Elmer Piros initiated coverage of MannKind with a Buy rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
- MannKind to in-license iSPERSE technology from Pulmatrix
- Pulmatrix enters cross license agreement with MannKind
- MannKind reports Q1 EPS 5c, consensus 3c